Literature DB >> 6488153

Cancer therapy with chemically modified enzymes. II. The therapeutic effectiveness of arginase, and arginase modified by the covalent attachment of polyethylene glycol, on the taper liver tumor and the L5178Y murine leukemia.

K V Savoca, F F Davis, T van Es, J R McCoy, N C Palczuk.   

Abstract

Monomethoxypolyethylene glycol (PEG) was attached covalently to arginase. PEG-arginase was effective in prolonging the survival times of mice injected with the Taper liver tumor, whereas unmodified arginase was ineffective. PEG-arginase was more effective than arginase in the in vitro destruction of L5178Y mouse leukemia. However, neither PEG-arginase nor arginase inhibited the in vivo growth of this tumor.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6488153

Source DB:  PubMed          Journal:  Cancer Biochem Biophys        ISSN： 0305-7232


  12 in total

1.  Strategies for optimizing the serum persistence of engineered human arginase I for cancer therapy.

Authors:  Everett Stone; Lynne Chantranupong; Candice Gonzalez; Jamye O'Neal; Mridula Rani; Carla VanDenBerg; George Georgiou
Journal:  J Control Release       Date:  2011-10-06       Impact factor: 9.776

2.  Arginine deprivation and tumour cell death: arginase and its inhibition.

Authors:  Denys N Wheatley; Ruth Philip; Elaine Campbell
Journal:  Mol Cell Biochem       Date:  2003-02       Impact factor: 3.396

Review 3.  Arginine catabolism, liver extracts and cancer.

Authors:  Denys N Wheatley; Elaine Campbell
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

Review 4.  Arginine depriving enzymes: applications as emerging therapeutics in cancer treatment.

Authors:  Neha Kumari; Saurabh Bansal
Journal:  Cancer Chemother Pharmacol       Date:  2021-07-26       Impact factor: 3.333

Review 5.  Importance of solid lipid nanoparticles (SLN) in various administration routes and future perspectives.

Authors:  Melike Uner; Gülgün Yener
Journal:  Int J Nanomedicine       Date:  2007

6.  Arginine deprivation therapy for malignant melanoma.

Authors:  Jung-Ki Yoon; Arthur E Frankel; Lynn G Feun; Suhendan Ekmekcioglu; Kevin B Kim
Journal:  Clin Pharmacol       Date:  2012-12-27

7.  Pegylated derivatives of recombinant human arginase (rhArg1) for sustained in vivo activity in cancer therapy: preparation, characterization and analysis of their pharmacodynamics in vivo and in vitro and action upon hepatocellular carcinoma cell (HCC).

Authors:  Sam-Mui Tsui; Wai-Man Lam; Tin-Lun Lam; Hiu-Chi Chong; Pui-Kin So; Sui-Yi Kwok; Simon Arnold; Paul Ning-Man Cheng; Denys N Wheatley; Wai-Hung Lo; Yun-Chung Leung
Journal:  Cancer Cell Int       Date:  2009-04-17       Impact factor: 5.722

Review 8.  Amino Acid Metabolic Vulnerabilities in Acute and Chronic Myeloid Leukemias.

Authors:  Aboli Bhingarkar; Hima V Vangapandu; Sanjay Rathod; Keito Hoshitsuki; Christian A Fernandez
Journal:  Front Oncol       Date:  2021-07-01       Impact factor: 6.244

9.  An Engineered Arginase FC Protein Inhibits Tumor Growth In Vitro and In Vivo.

Authors:  Lihua Li; Yan Wang; Jun Chen; Bi Cheng; Jiehua Hu; Yuehua Zhou; Xin Gao; Liucun Gao; Xifan Mei; Meiyan Sun; Zhuomei Zhang; Haifeng Song
Journal:  Evid Based Complement Alternat Med       Date:  2013-05-08       Impact factor: 2.629

10.  Arginine deprivation, growth inhibition and tumour cell death: 2. Enzymatic degradation of arginine in normal and malignant cell cultures.

Authors:  R Philip; E Campbell; D N Wheatley
Journal:  Br J Cancer       Date:  2003-02-24       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.